PMID- 11011806
OWN - NLM
STAT- MEDLINE
DCOM- 20010208
LR  - 20191104
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 26 Suppl 1
DP  - 2000
TI  - Prophylaxis and treatment of deep-vein thrombosis.
PG  - 47-52
AB  - In 1980, unfractionated heparin (UFH) was the established agent for the 
      prophylaxis of venous thromboembolic (VTE) disease in patients undergoing general 
      surgery. VTE prophylaxis was the first indication in which low-molecular-weight 
      heparins (LMWHs) were tested. Approximately 40 trials have demonstrated that 
      LMWHs are at least as effective and safe as UFH. LMWHs exhibit a number of 
      advantages over UFH, including ease of administration, convenient once-daily 
      dosing, and facilitation of outpatient management. The ideal time of 
      administration and the dose of the initial one or two injections of LMWH remain 
      unresolved issues. LMWHs are used with increasing frequency in the treatment of 
      acute deep vein thrombosis (DVT), having been studied in comparison to UFH in 16 
      major clinical trials. LMWHs are at least as effective as UFH in the prevention 
      of VTE, but higher doses than those used for prophylaxis are required. There is 
      still an ongoing debate about whether the daily dose should be administered in 
      one or two subcutaneous injections. In some recent studies, symptomatic new DVTs 
      or pulmonary emboli (PE) were the primary end points, which had to be verified by 
      objective methods, but such end points may be not be sensitive enough to detect 
      major differences in the efficacy of different LMWHs.
FAU - Breddin, H K
AU  - Breddin HK
AD  - International Institute for Thrombosis and Vascular Diseases, Frankfurt Main, 
      Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Female
MH  - Heparin/standards/therapeutic use
MH  - Heparin, Low-Molecular-Weight/standards/*therapeutic use
MH  - Humans
MH  - Male
MH  - Venous Thrombosis/*drug therapy/*prevention & control/surgery
RF  - 50
EDAT- 2000/09/30 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/09/30 11:00
PHST- 2000/09/30 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/09/30 11:00 [entrez]
AID - 10.1055/s-2000-9493 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2000;26 Suppl 1:47-52. doi: 10.1055/s-2000-9493.